M. Takizawa

Investigation of Safety and Tolerability of ASP3652 Based on Clinical Studies of Cerebrospinal Fluid Transfer After Multiple Doses and Exposure After Single Doses at High Dose Levels

I. Michon, J. Meijer, D. Cerneus, 2020, Advances in Therapy.

The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects

I. Michon, J. Meijer, D. Cerneus, 2020, Advances in Therapy.

Randomized, Double‐Blind, Controlled Study to Evaluate Safety and Pharmacokinetics of Single Ascending Doses of ASP5354, an Investigational Imaging Product, in Healthy Adult Volunteers

B. Gufford, L. Galitz, Stephen Flach, 2021, Clinical pharmacology in drug development.

Telecommunication system for children undergoing stem cell transplantation

K. Koike, Y. Nakazawa, Miyuki Tanaka, 2011, Pediatrics international : official journal of the Japan Pediatric Society.

Manipulation of diacylglycerol and ERK-mediated signaling differentially controls CD8+ T cell responses during chronic viral infection

Taku Yoshida, T. Kambayashi, Y. Okada, 2022, Frontiers in Immunology.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652, a Reversible Fatty Acid Amide Hydrolase Inhibitor, in Healthy, Nonelderly, Japanese Men and Elderly, Japanese Men and Women: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Phase I Study.

M. Katashima, H. Nagashima, M. Takizawa, 2020, Clinical therapeutics.

Hypotensive effect of a phosphorus-containing novel angiotensin converting enzyme inhibitor, (S)-1-[6-amino-2[[hydroxy(4-phenylbutyl)phosphinyl] oxy]-1-oxohexyl]-L-proline (SQ 29,852) in conscious hypertensive dogs.

N. Ogawa, N. Ohara, H. Ono, 1992, Journal of pharmacobio-dynamics.

Pharmacological studies of a novel cardiotonic agent, pimobendan (UD-CG 115 BS)

Y. Ishiguro, N. Ohara, M. Takizawa, 1992 .